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Background: Fecal bacteriotherapy (‘stool transplant’) can be effective in treating recurrent Clostridium difficile
infection, but concerns of donor infection transmission and patient acceptance limit its use. Here we describe the
use of a stool substitute preparation, made from purified intestinal bacterial cultures derived from a single healthy
donor, to treat recurrent C. difficile infection that had failed repeated standard antibiotics. Thirty-three isolates were
recovered from a healthy donor stool sample. Two patients who had failed at least three courses of metronidazole
or vancomycin underwent colonoscopy and the mixture was infused throughout the right and mid colon.
Pre-treatment and post-treatment stool samples were analyzed by 16 S rRNA gene sequencing using the Ion
Torrent platform.
Results: Both patients were infected with the hyper virulent C. difficile strain, ribotype 078. Following stool
substitute treatment, each patient reverted to their normal bowel pattern within 2 to 3 days and remained
symptom-free at 6 months. The analysis demonstrated that rRNA sequences found in the stool substitute were rare
in the pre-treatment stool samples but constituted over 25% of the sequences up to 6 months after treatment.
Conclusion: This proof-of-principle study demonstrates that a stool substitute mixture comprising a multi-species
community of bacteria is capable of curing antibiotic-resistant C. difficile colitis. This benefit correlates with major
changes in stool microbial profile and these changes reflect isolates from the synthetic mixture.
Trial registration: Clinical trial registration number: CinicalTrials.gov NCT01372943
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Clostridium difficile infection (CDI) is a bacterial disease
of the gastrointestinal tract caused by C. difficile, a toxin-
producing, Gram-positive, anaerobic, spore-forming bacil-
lus. CDI accounts for 15 to 25% of antibiotic-associated
diarrhea [1]. The infection occurs most commonly when
patients receive antibiotics that alter their normal enteric
gut bacteria, allowing overgrowth of C. difficile. Recom-
mended therapy for CDI consists of either metronidazole
or oral vancomycin [2].* Correspondence: eop@queensu.ca
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reproduction in any medium, provided the orRecurrent CDI is defined as complete resolution of CDI
while on appropriate therapy followed by recurrence of
CDI after treatment has been stopped [3]. An association
has been made between recurrent disease and intestinal
dysbiosis [4], and an inability of certain individuals to re-
establish their normal intestinal bacteria is thought to play
a leading role in recurrence. Unfortunately, few effective
treatments exist for those patients with multiple recur-
rences of CDI, a debilitating disease. Fecal bacteriotherapy,
or ‘stool transplant’ – infusing donor stool into the intes-
tine of the recipient to re-establish normal bacterial
microbiota – has shown promising results in preliminary
studies [3,5] but concerns about pathogen transmission,
patient acceptance and inability to standardize the treat-
ment regimen remain. The aim of this study was totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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accomplished with a stool substitute. Here we report the
successful outcome of two patients with recurrent CDI
unresponsive to conventional therapy who received a stool
substitute, a preparation of 33 different intestinal bacteria
isolated in pure culture, from a single healthy donor.Methods
Study design
The study protocol, in accordance with Good Clinical
Practice Guidelines, was approved by the Human Re-
search Ethics Boards at Queen’s University and the Uni-
versity of Guelph, and meets the provisions of the
Helsinki Declaration (1964, amended in 2008) of the
World Medical Association.
Inclusion criteria for the study included a history of pre-
vious CDI, confirmed by C. difficile fecal toxin immuno-
assay, new onset of symptoms after completing a full
course of medication for CDI, positive C. difficile toxin
assay confirming recurrent CDI, and age 18 years or older.
Patients were assessed by specialists in Infectious Disease
and Gastroenterology, and other possible causes of diar-
rhea were ruled out. Two patients who fulfilled the inclu-
sion criteria were enrolled in the study and written
informed consent was obtained.Microbiology
Development and preparation of RePOOPulate
The RePOOPulate human probiotic or synthetic stool
mixture was developed by extensively culturing the mi-
crobial diversity from the stool of a healthy, 41-year-old
female donor. Sixty-two different bacterial isolates
were recovered on various media types (including Brain
Heart Infusion agar, Wilkins–Chalgren agar, Reinforced
Clostridial Agar, and deMan, Rogosa & Sharpe agar)
using strict anaerobic conditions (to recover both strict
and facultative anaerobes). Purified isolates were identi-
fied by 16S rRNA gene sequencing and were subjected
to antibiotic susceptibility profiling. Susceptibility to
antimicrobials was determined either by directly measur-
ing susceptibility or through inference based on other
cultivated representatives. For instance, in cases where
minimum inhibitory concentration breakpoints are not
documented, susceptibility was determined using Kirby–
Bauer discs for select antibiotics known to have anaerobic
activity; if the bacterial lawn grew up to the edge of the
disc, then it was considered resistant and that isolate was
not used. For isolates where there was a zone of inhibition
of questionable significance, an acceptable level of inhib-
ition was inferred based on other cultivated representa-
tives. If there was any doubt, and the organism was at all
suspected to be resistant, then it was not used in the
mixture.Thirty-three isolates, representing commensal spe-
cies that were generally sensitive to a range of antimi-
crobials and were relatively straightforward to culture,
were selected for the final stool substitute formulation.
Full-length 16 S rRNA sequences were aligned with
the NAST server [6], and were then classified using the
GreenGenes classification server [7]. The most specific
name in the GreenGenes classification was used and
we report the DNA maximum likelihood score for each
classification (Table 1).
To infer a relative ratio of the selected isolates for inclu-
sion in the formulated RePOOPulate product, a compari-
son of our list of cultured bacterial species was made with
the MetaREP metagenomic database collection of stool
sample datasets from healthy donors [8]. Using the tax-
onomy browser, the dataset that most closely matched our
profile of cultured isolates (SRS058723) was selected and
used as a guide for inference of relative abundance of each
species – with the exception that Bifidobacterium spp.
were added to higher abundances, reflecting the widely
observed underestimated abundances of Actinobacteria,
and specifically this genus, in metagenomic analyses of
human stool [9,10]. An approximate ratio based on cul-
tured cell biomass, measured using standard 10 μl micro-
biological loops, was generated (Table 1).
Each of the 33 isolates was individually cultured on
Fastidious Anaerobe Agar (Lab M Ltd. Heywood,
Lancashire, UK) under anaerobic conditions, and then
cultures were formulated into the predetermined ratio, as
described above, in 100 ml pre-reduced sterile 0.9% nor-
mal saline to an estimated concentration of 3.5 × 109
colony-forming units/ml. The bacterial suspension was
placed in a reduced atmosphere in a double-sealed con-
tainer at 4°C, and used within 24 hours of preparation.
Isolation and ribotyping of C. difficile from patient stool
samples
C. difficile was isolated from stool samples according to
methods described previously [11], using selective media
of moxalactam norfloxacin broth (CDMN; Oxoid, Nepean,
Ontario, Canada) enriched with 0.1% sodium tauro-
cholate. Isolates were typed using the PCR ribotyping
method described by Bidet and colleagues [12].
Administration of stool substitute
Antibiotic therapy was withheld for 2 days and the
patients underwent standard colon cleansing the even-
ing prior to colonoscopy. The following morning dur-
ing colonoscopy, one-half (50 ml) of the solution was
deposited in the region of the cecum/proximal ascend-
ing colon and the other half was drizzled throughout
the transverse colon as the colonoscope was withdrawn.
Both patients were noted to have significant diverticular dis-
ease. Immediately post procedure, patients were maintained
Table 1 Composition of stool substitute (RePOOPulate)
Closest species match, inferred by alignment
of 16S rRNA sequence to GreenGenes databasea
% identity to closest
match
Relative abundance (by biomass)
in RePOOPulate formulation
Acidaminococcus intestinalis 100 +++
Bacteroides ovatus 99.52 +
Bifidobacterium adolescentis (two different strains) 99.79 ++
99.79 ++
Bifidobacterium longum (two different strains) 99.86 +++
99.16 +++
Blautia producta 96.43 +
Clostridium cocleatum 91.92 +
Collinsella aerofaciens 98.73 +
Dorea longicatena (two different strains) 99.62 +
99.60 +
Escherichia coli 99.80 +
Eubacterium desmolans 94.90 +
Eubacterium eligens 98.15 +++++
Eubacterium limosum 97.05 +




Eubacterium ventriosum 100 ++
Faecalibacterium prausnitzii 99.17 +++++
Lachnospira pectinoshiza 95.22 +
Lactobacillus casei/paracasei 99.47 +
Lactobacillus casei 99.74 +
Parabacteroides distasonis 99.45 ++
Raoultella sp. 99.40 +
Roseburia faecalis 99.65 ++
Roseburia intestinalis 100 ++
Ruminococcus torques (two different strains) 99.15 +++
99.29 +++
Ruminococcus obeum (two different strains) 94.89 +
94.69 +
Streptococcus mitisb 99.79 +
List of cultured isolates from the healthy donor, with favorable antibiotic resistance profiles (defined as vancomycin and/or imipenem sensitive, with further
sensitivity to at least three of piperacillin, amoxicillin/clavulanic acid, ceftazidime, ceftriaxone, moxifloxacin and metronidazole) that were included in the stool
substitute preparation. aClosest species match was inferred by alignment of the 16S rRNA sequence to the GreenGenes database [7]; note that in some cases 16S
rRNA gene sequences could not resolve identity beyond genus, and that closest match does not infer definitive speciation. Shaded boxes indicate strains that are
possibly novel species (and, in some cases, genera). Note that some representative strains identify with the same species by 16S rRNA gene sequence alignment,
but we believe them to be different strains based on differences in colony morphology, antibiotic resistance patterns and growth rates. bIdentifies with S. mitis
but is not β-hemolytic.
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being discharged home. Patients were instructed to eat
a fiber-rich diet and not to consume products contain-
ing probiotics. Patients were followed by a study nurse
to obtain stool samples and closely monitor their clin-
ical response.Sequence analysis
gDNA extraction from stool samples
gDNA was extracted using a protocol involving a combin-
ation of bead beating, the E.Z.N.A.W Stool DNA Kit (Omega
Bio-Tek, Norcross, Georgia, USA) and the MaxwellW 16
DNA Purification Kit (Promega, Madison, Wisconsin, USA).
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10 μl of 20 mg/ml proteinase K (in 0.1 mM CaCl2) and
200 mg glass beads were added to a screw-capped Eppen-
dorf tube and disrupted in a bead beater for 3 minutes. Fol-
lowing subsequent incubation at 70°C for 10 minutes and at
95°C for 2 minutes, 100 μl E.Z.N.A. Kit Buffer P2 was added
to each sample and incubated on ice for 5 minutes. Samples
were then centrifuged at 14,000 × g for 5 minutes, and the
supernatant transferred into new tubes, each containing
200 μl E.Z.N.A. Kit HTR reagent. Following thorough mix-
ing, samples were incubated at room temperature for 2 min-
utes and centrifuged at 14,000 × g, and the supernatant was
transferred into MaxwellW 16 DNA Purification Kit car-
tridges. The remainder of the DNA extraction protocol was
carried out in the MaxwellW 16 Instrument according to the
manufacturer’s instructions (Promega).
V6 rRNA amplification
PCR amplification of the bacterial V6 rRNA region was
carried out with the left-side primer CWACGCGAR
GAACCTTACC and the right-side primer ACRACAC
GAGCTGACGAC. These primer sequences were chosen
because they are exact matches to >95% of the rRNA
sequences from organisms identified in the human micro-
biome project (GBG, unpublished observations). In
addition the left-side primers contained the standard Ion
Torrent (Ion Torrent Systems Inc., Guilford, Connecticut,
USA) adapter and key sequence at their 50 end (CCATCT
CATCCCTGCGTGTCTCCGACTCAG). One of the fol-
lowing 5-mer barcodes was located between the 30 end
of the key sequence and the 50 end of the primer:
TATCG, TAGAC, TGCAT, ATGAG, ACAGT, AGATG,
CTCAC, CTGTA, CGTGA, CGACT, AACTC, or
CCTAT. Duplicate samples did not use the same bar-
codes. The right-side primer had the other standard
Ion Torrent adapter sequence (CCTCTCTATGGG
CAGTCGGTGAT) attached to its 50 end. Amplification
was performed for 25 cycles in 40 μl using the colorless
GO-Taq hot start master mix (Promega) according to the
manufacturer's instructions with the following three-step
temperature profile: 95°C, 55°C and 72°C for 1 minute
each step, then 5 μl of the resulting amplification were
quantified using the QuBit broad-range double-stranded
DNA fluorometric quantitation reagent (InVitroGen, Life
technologies Inc., Burlington, Ontario, Canada). Samples
were pooled at approximately equal concentrations and
purified using a Wizard PCR Clean-Up Kit (Promega).
Sequencing
Sequence reactions were carried out on the Ion Torrent
314 and 316 chip platform. Up to 12 samples were mul-
tiplexed on each chip through use of individual sequence
tags. Data from all runs were pooled when samples were
run on more than one chip.Sequence data processing
Five sequencing reactions were carried out on the Ion
Torrent platform: three reactions on a 314 chip and two
reactions on the 316 chip. The chips differ only in the
density of the spots, and hence in the amount of se-
quence that can be obtained (the 316 chip is about five
to six times as dense as the 314 chip). The sequence was
provided in fastq format. All sequences were then fil-
tered according to the following criteria: exact matches
to the barcodes used, exact match to the left-side primer
including redundant positions in the primer, an exact
match to the first six nucleotides of the right-side pri-
mer, and a length between the left-side and right-side
primer of between 71 and 83 nucleotides. This length
was chosen because it encompasses the predicted ampli-
con product size from all human-associated bacterial
organisms that have been cultured and sequenced as
part of the human microbiome project.
Approximately 40 to 50% of the reads passed these fil-
ters in the most recent Ion Torrent runs; reads not pas-
sing the filters were not examined further. Reads were
processed as described by Gloor and colleagues [13] ex-
cept that clustering with USEARCH was performed at
97% identity. Chimera detection was performed with
UCHIME (version v5.2.32) using the de novo method
[14]. Only four chimeric sequences were observed out of
30,419 unique sequences in the merged dataset, and all
were rare. This frequency is similar to that reported pre-
viously for amplification and sequencing of the V6 rRNA
region using the Illumina platform [13]. Chimeric
sequences were not considered an issue in this dataset.
A table of counts for sequences grouped at the 97%
operational taxonomic unit (OTU) and 100% identical
sequence unit identity level were generated for each
sample as before [13], keeping all identical sequence unit
or OTU sequences that were represented in any sample
at a frequency >0.5%. Reads that were never abundant in
any sample (<0.5%) were grouped into the remainder
and discarded. Between 12.6 and 51.9% (median 31%) of
the identical sequence unit reads and between 1.4 and
17.2% (median 5.8%) of the OTU reads were in the re-
mainder group. These values are approximately five
times greater than those observed for identical sequence
units sequenced on the Illumina platform but are about
equivalent to the Illumina platform observations when
reads were clustered.
Taxonomic classification
Classification of the sequences by either the GreenGenes
or RDP classifiers proved to be unreliable because of the
short length of the V6 region. Classification of the
sequences present in the count table was therefore per-
formed using the RDP closest match option on the full-
length, high-quality, isolated subset. The maximum number
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of the best match and ties was collected. The classification
of those hits was adopted for all levels where the classifica-
tion was identical across all best matches, otherwise the clas-
sification was marked as undefined. The V6 region is not
able to resolve the genus or species level of a number of
clades, so all analyses were carried out at the family level.
This strategy worked for all abundant families – with the ex-
ception of the Bifidobacterium, which were annotated as
such from BLAST searches of the NCBI microbial 16 S
rRNA database. The taxonomic classification was added to
the sequence count table and the data were presented in for-
mats that could be accepted by QIIME 1.5.0 [15] as follows.
Sequence alignments were built using Muscle [16] and a
neighbor-joining tree was generated by ClustalW2 [17].
Beta-diversity was calculated by the UniFrac algorithm [18].
Tables were imported into MacQIIME, which is an OS X





Patient 1 was a 74-year-old Caucasian woman who pre-
sented with six episodes of recurrent CDI (confirmed by
C. difficile toxin assay) over an 18-month period, all of
which required hospitalization. The first episode of CDI
developed after elective orthopedic surgery (knee arthro-
plasty), when the patient received preoperative cefazolin
(Figure 1A). After treatment with the stool substitute,
she reverted to her normal bowel pattern of a formed
stool every 1 or 2 days. No C. difficile was detectable by
C. difficile toxin assay at 10 days post procedure. Patient
1 did receive several courses of antibiotics for recurrent
urinary tract infections in the subsequent weeks follow-
ing her stool substitute treatment, but her diarrhea did
not recur. She remained symptom-free at the last evalu-
ation, 24 weeks after treatment. Two different strains of
C. difficile were isolated from the pre-treatment sample.
One strain was identified as ribotype 078; the other was
a less common toxinotype 0 ribotype (data not shown).
Patient 2
Patient 2 was a 70-year-old Caucasian woman with a
history of peripheral neuropathy, which predisposed her
to recurrent skin and soft tissue infections. She devel-
oped her initial CDI after receiving cefazolin for cellulitis
and presented to the clinic with a history of three epi-
sodes of recurrent CDI, the last of which had failed
standard medical therapy (Figure 1B). After receiving the
study treatment, she reported formed bowel movements
within 72 hours. She remained symptom-free for 3 weeks,
then developed recurrent cellulitis and was placed on cef-
triaxone by her physician. She was monitored closelywhile on ceftriaxone but did not develop loose stool or
diarrhea. She suffered from several skin and soft tissue
infections in the subsequent weeks and received several
additional courses of broad-spectrum antibiotics for these
infections. Nevertheless, she remained symptom-free with
no diarrhea at last evaluation, which was 26 weeks post
procedure. Ribotype 078 was also isolated from this
patient’s pre-treatment sample.
Sequence analysis
Reproducibility of the data
The Ion Torrent instrument has not previously been
used for community microbial composition analysis with
amplified rRNA variable regions. We therefore first
examined the reproducibility of the reads obtained on
the instrument by performing three separate PCR ampli-
fications of the V6 rRNA region and sequencing these
amplifications on four separate Ion Torrent runs. The
PCR reactions were amplified by two separate indivi-
duals on separate days. A separate library was prepared
from each amplification. Each library was run on either
a 314 or a 316 Ion Torrent chip, with one library run on
two separate chips. In this way the technical replication
both of the amplification and of the sequencing reaction
could be assessed.
The number of reads obtained for these sequencing
reactions was often small – especially for the initial run on
the 314 chip, which has limited capacity – and is summar-
ized in Table 2. Reads were processed by the standard
pipeline outlined in Methods, and an unweighted pair
group method with arithmetic mean distance tree was
generated from the beta-diversity output by QIIME. The
result (shown in Figure 2) demonstrates that all the ampli-
fications from each of the four replicates clustered to-
gether by sample – with the exception of one of the
Patient 1 day 2 and week 2 samples, which showed clus-
tering together by the amplification. Note, however, the
very short branch lengths in this clade, indicating that
these samples are probably indistinguishable. All further
analyses used pooled reads across all replicates for each
sample.
Examination of alpha-diversity
In total, there were between 3,758 and 76,752 V6 rRNA
reads per sample for Patient 1 and between 19,751 and
64,200 reads per sample for Patient 2 using the Ion Tor-
rent instrument as outlined in Methods. These reads
were processed by a combination of custom scripts and
the QIIME pipeline as described in Methods. Reads were
clustered at 97% sequence identity for the analysis that
follows, unless stated otherwise. Read counts were nor-
malized using rarefaction to the minimum number of
reads per sample in each patient, and Shannon's diver-
sity index was plotted for each intermediate rarefaction
Figure 1 Clinical timeline of events for Patients 1 and 2. Sequence of events for the first two patients enrolled in the study. (A) Patient 1 had
Clostridium difficile initially occurring after a pre-operative course of cefazolin for elective total knee arthroplasty. (B) Patient 2 had C. difficile
initially occurring after a course of cefazolin for cellulitis. Both patients had multiple courses of antibiotic treatment for the C. difficile infection
with both vancomycin and metronidazole prior to enrollment, as indicated. In addition, Patient 1 received the probiotic Saccharomyces boulardii.
Prior to treatment with the stool substitute preparation RePOOPulate (RP), stool collection on each patient was carried out at 2 days pre
treatment (PT), day 2 post treatment (D2), week 2 post treatment (W2), week 4 post treatment (W4), and 6 months post treatment (6 M). Toxin
assays for C. difficile were also performed (purple boxes), with results as shown. Incidental antibiotic use post treatment is indicated. AMX,
amoxicillin; CFZ, cefazolin; CIP, ciprofloxacin; CLI, clindamycin; CRO, ceftriaxone; LEX, cephalexin; MTZ, metronidazole; NIT, nitrofurantoin; SXT,
trimethoprim-sulfamethoxazole; VAN, vancomycin.
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mean Shannon's diversity index of 10 rarefaction sam-
ples approximated the diversity index of the total dataset
when the number of rarefied samples exceeded 1,000
(data not shown). This observation indicates that we
obtained sufficient reads in all samples to accurately esti-
mate the diversity. Shannon's diversity on the total data-
set for all samples is given in Table 3, from which we see
that the two patients had dramatically different Shannon'sdiversity scores before and after treatment. Patient 1 had a
highly diverse microbiota that became less diverse after
treatment, and over time tended to become more diverse.
At 6 months post treatment, this patient had a diversity
score that was almost the same as that at pre treatment.
Patient 2 initially had a low diversity microbiota, which
became more diverse following treatment and stabilized
over the long term at a level that was more diverse than
that at pre treatment.
Table 2 Read numbers for sequencing reactions obtained
on the Ion Torrent platform
Run ID Person Barcode Sample Reads
1 pg15 G2 TAGAC D2 1,568
1 pg15 G2 TATCG PT 1,058
1 pg15 G2 AGATG RP 1,439
1 pg15 G2 TGCAT W2 1,927
1 pg15 G2 ACAGT W4 1,319
2 pg23 G1 TAGAC D2 782
2 pg23 G1 TATCG PT 655
2 pg23 G1 ATGAG RP 920
2 pg23 G1 TGCAT W2 981
2 pg23 KC CTGTA D2 2,506
2 pg23 KC CTCAC PT 524
2 pg23 KC CGACT RP 702
2 pg23 KC CGTGA W2 3,519
2 pg25 G2 TAGAC D2 1,082
2 pg25 G2 TATCG PT 532
2 pg25 G2 AGATG RP 526
2 pg25 G2 TGCAT W2 925
2 pg25 G2 ACAGT W4 563
D2, day 2 post treatment; PT, 2 days pre treatment; RP, RePOOPulate
preparation; W2, week 2 post treatment; W4, week 4 post treatment.
Figure 2 Distance tree of weighted UniFrac distances between sampl
tree calculated by the unweighted pair group method with arithmetic mea
RePOOPulate formulation. Post-treatment samples are colored green (D2),
underscore character and the fields are: Ion Torrent run ID, person and tim
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Taxonomic assignments of the seed sequences for each
OTU were derived from best-hit analysis of the
sequences in the RDP database as explained in Methods.
Briefly, the full taxonomic lineage of the 20 best hits and
ties was captured using a custom Perl script and added
to the QIIME input tables. Any lineage where the best
hits and ties were not in full agreement was annotated
as undefined. Taxonomic assignment was carried out to
the family level since the rRNA V6 region has poor reso-
lution below this taxonomic level for several groups
found in our dataset, such as the Gammaproteobacteria
and Lachnospiraceae families. Beta-diversity taxonomic
bi-plots at the family level were generated using the
QIIME package with default values for the read counts
of the samples derived from each individual patient in-
cluding the initial RePOOPulate sample (Figure 3). In
both patients, the first three principle components cap-
tured over 85% of the variation between the samples.
The taxonomic distribution of reads in the two
patients was noticeably different, however, as shown in
the barplots of Figure 4 – as was the trajectory of the
microbiome composition after treatment. The micro-
biota of Patient 1 initially had a number of distinct fam-
ilies from the Firmicutes phylum. Samples collected at
day 2 and at week 2 were largely composed of familieses for Patient 1 amplified and sequenced independently. Distance
n. Branch tips are colored by sample: red, pre-treatment; blue,
cyan (W2), and purple (W4). Tip label fields are separated by an
e of amplification, sample identifier, barcode sequence.
Table 3 Shannon diversity values calculated for
nonrarefied count values
Patient PT D2 W2 W4 6 M RP
1 5.1 3.1 3.4 5.0 5.2 4.1
2 3.2 3.5 4.2 3.8 3.9 4.1
D2, day 2 post treatment; 6 M, 6 months post treatment; PT, 2 days pre



















































Figure 3 Principle component coordinates of patient time points and
UniFrac principle coordinates were generated by QIIME for each patient in
for the RePOOPulate formula, and as the day (D), week (W) or month (M) t
level taxonomic groups is indicated by the size and position of the open c
day 2 and week 2 post-treatment samples, less abundant in the week 4 po
most abundant groupings of organisms are shown, and these differ betwe
in both.
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4 weeks were composed of similar fractions of families
in these two phyla. After 6 months this patient had a
microbiota that was largely composed of Firmicutes. In
contrast, the microbiota of Patient 2 was largely com-
posed of Proteobacteria before treatment, and was no-
ticeably lacking in Actinobacteria and Bacteriodetes
phyla. The fraction of Proteobacteria declined rapidly
after treatment, initially displaced by families from the
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most abundant sequences clustered at family level. Weighted
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ime point post treatment. The weighted mean abundance of family-
ircles. For example, for Patient 1 Bacteriodaceae are abundant in the
st-treatment sample, and are rare in all other samples. Only the 10



























































Figure 4 Barplot of abundance at the family level. Operational taxonomic units (OTUs) that comprised more than 0.5% of the OTUs in any
sample were grouped into the appropriate family and plotted. These plots show how the actual composition of each sample changes over time.
Note that the two patients had very different initial microbiota compositions. The compositional differences were maintained at all time points,
suggesting that environmental or genetic factors were important in shaping community structure.
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Actinobacteria and an increase in Bacteriodetes and
Firmicutes. The Proteobacteria were displaced com-
pletely by 2 weeks. After 6 months this patient’s micro-
biota was composed largely of families drawn from the
Firmicutes and of Verrucomicrobia phyla.
Long-term colonization
We were interested in determining the ability of the
organisms composing the RePOOPulate formulation to























Figure 5 Weighted abundance overlap at the identical sequence unit
of sequence counts that correspond exactly to those in the RePOOPulate (
time post treatment. Red, RP formulation; dark blue, samples from Patient 1
identical to the RP reads immediately after treatment, and a steady decline
patients had similar RP-identical reads at 6 months post treatment, even ththat the weighted UniFrac distances between the sam-
ples at pre treatment and 6 months post treatment in
Patient 1 were less than those between either sample
and any other. In contrast, the earliest time point for Pa-
tient 2 was most similar to the pre-treatment sample.
These relationships can be seen in Figures 3 and 4, but
are clearer in Figure S1 in Additional file 1. However,
there was one common feature between the microbiota
trajectories of the two patients. Figure 5 shows plots of
the weighted fraction of sequences that were identical to























and 97%-clustered operational taxonomic unit levels. Proportion
RP) formulation and found in each patient sample as a function of
; cyan, samples from Patient 2. There is an initial increase in reads
in proportion for each patient with time since treatment. Both
ough their microbiota profiles were different.
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though the initial taxonomic distribution of the patients
was very different (Figures 3 and 4), the initial fraction
of reads identical to the RePOOPulate reads was <7%
when clustered at 100% identity, and was between 7 and
9.5% when clustered at 97% identity. Not surprisingly,
the fraction of reads identical to those derived from the
RePOOPulate sample increased rapidly after treatment
such that reads identical to the RePOOPulate reads
2 days to 2 weeks after treatment composed >70% of the
total reads in Patient 1 (day 2 post treatment) and 50%
in Patient 2 (week 2 post treatment). The fraction of the
patient microbiota that was composed of reads identical
to those found in RePOOPulate declined continuously
from the sample 2 weeks post treatment onwards, and at
6 months these reads were found to compose between 25
and 36% of the total reads obtained from each patient. This
emergent pattern of slow loss of reads identical to reads in
the RePOOPulate sample was common to both patients.
Discussion
This pilot study shows that a synthetic stool (stool sub-
stitute) may be an effective and feasible alternative to
the use of defecated donor fecal matter (stool transplant)
in the treatment of recurrent CDI. Given the marked
differences between the two patients in the study, it is
difficult to draw conclusions that might be broadly ap-
plicable to a larger patient population at this time and
clearly more patients are needed. Nevertheless, the clin-
ical cure achieved at 6 months of follow-up demon-
strates feasibility of this approach as an alternative to
conventional stool transplant. A synthetic stool substi-
tute approach has multiple advantages: the exact com-
position of bacteria administered is known and can be
controlled; the bacterial species composition can be
reproduced, should a future treatment be necessary; pre-
parations of pure culture are more stable than stool,
which some groups recommend should be collected
fresh and instilled into the recipient within 6 hours of
collection [19]; an absence of viruses and other patho-
gens in the administered mixture can be ensured,
thereby improving patient safety; and the administered
organisms can be selected based on their sensitivity to
antimicrobials, allowing an enhanced safety profile.
Recurrent CDI is thought to be largely due to the inability
of the normal intestinal microflora to recover and re-
establish itself [4,20,21]. We used the Ion Torrent platform
to analyze the 16 S rRNA gene profiles of stool samples col-
lected from each patient during the study, and carried out
exhaustive quality control of our data. We concluded that
this sequencing platform, together with the PCR amplifica-
tion protocol and bioinformatic analysis pipeline, was ad-
equate to reproducibly separate both technical replicate
samples (Figure 2).Our study showed that the microbiota of both patients
adapted characteristics of the stool substitute mixture yet
still retained some of their original microbiota, similar to
that described for stool transplants [20]. However, our
data suggest that decreased diversity as a risk factor for re-
current CDI may be less important than the actual organ-
isms present in the mixture per se, since Patient 1 actually
had a very diverse microbiome at the outset but still suf-
fered from severe recurrent CDI. Sequences identical to
those of the stool substitute bacteria were initially rare in
the pre-treatment samples for both patients (<7%), but be-
came transiently abundant and constituted over 25% of
the sequences up to 6 months after stool substitute treat-
ment was given. Hence, we conclude that some of the
administered bacteria are stably colonizing the colon, an
important observation since most commercially available
probiotics only transiently colonize the intestine. These
data along with the very different set of RePOOPulate
organisms that were initially abundant suggest that other
factors, such as diet, may play an active role in influencing
the microbial communities over time. These data suggest
that a multi-species derivative community such as that
used here will be more generally useful than a single or-
ganism probiotic or a mixed culture of such probiotic spe-
cies, because the microbes in RePOOPulate are derived
from a community and probably retain some community
structure that enables them to colonize the appropriate
environment. In addition, the data also suggest that the
relative proportions of different bacterial strains in the for-
mulation are of only minor importance. Experiments to
determine the extent of the influence of therapeutic com-
munity composition on the resulting community profile
in the host are currently underway. Longer term experi-
ments colonizing animal models with the stool substitute
formulations will clarify the extent to which organisms
introduced as part of a gut microbial ecosystem are per-
turbed by antibiotic use, and the extent to which they per-
sist over longer time frames.
The question of whether age-matching of donors and
recipients of stool would be of relevance, since the iso-
lates used to formulate our stool substitute were derived
from a younger individual, is largely a matter of debate.
Many stool transplants have been performed successfully
in older patients using young donors that are often
related to the patient [22,23]. The treatment seems
equally effective when the young donors are not related
[19,23]. We therefore suspect that age-matching will not
turn out to be a critical factor in treatment success, al-
though this is a question that should be addressed by
careful meta-analysis of clinical trial data. Similarly, the
relevance of patient enterotype [24], which may turn out
to be more important than age-matching, has not been
fully explored. Experiments are currently underway in
our laboratories to develop further therapeutic synthetic
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known to exist in humans.
Both patients were infected with ribotype 078, an
emerging hypervirulent strain that has been associated
with community-associated CDI, as well as with live-
stock (pigs, cattle, poultry), and food products [25]. Like
NAP1/027, its prevalence seems to be increasing in
many countries [25]. Whether ribotype 078 will be more
commonly found in patients with recurrent CDI,
whether it is an emerging pathogen in this region or
whether its presence in these two non-epidemiologically
related patients was a chance finding remains to be seen.
Regardless, the stool substitute preparation used here
was effective at eradicating disease that had failed all
other treatment regimens. In addition, this study also
suggests that a defined microbial community, isolated
from a single healthy donor, may be robust enough to
withstand further perturbations by antibiotics as illu-
strated by the patients in our study. In the case of Pa-
tient 1, who suffered from occasional urinary tract
infections, the antibiotics used post procedure (cipro-
floxacin, nitrofurantoin and amoxicillin) were for short
courses only, up to a maximum of 7 days. For Patient 2,
her recurrent skin and soft tissue infections occasionally
necessitated a broad-spectrum antibiotic combination
(for example, cephalexin and metronidazole) of much
longer duration (4 weeks in one case). Despite post-
procedure administration of these incidental antibiotics
for infections unrelated to C. difficile colitis, neither pa-
tient developed further recurrent CDI. However, at this
time it remains unclear whether antibiotic administra-
tion affected the long-term colonization by the microbial
community used as treatment, or to what extent the dif-
ferences in microbial profile in the 6-month samples be-
tween patients is driven by the different antibiotics
administered. More controlled studies in animal models
may help to address some of these questions.
Conclusion
Further research is needed to define the mechanisms
and precise role for this stool substitute in treating CDI.
However, once a patient fails oral vancomycin therapy,
treatment options for recurrent CDI are very limited.
Ecosystem therapeutics or repopulating the bowel with
defined communities of normal intestinal bacteria offers
another effective therapy for treating recurrent CDI.Additional file
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